Peroxisome proliferation and beta-oxidation in Fao and MH1C1 rat hepatoma cells, HepG2 human hepatoblastoma cells and cultured human hepatocytes: effect of ciprofibrate.
Human HepG2, rat Fao and MH1C1 hepatoma cell lines have been examined for their response to ciprofibrate, a potent peroxisome proliferator. Changes in the morphological characteristics of peroxisomes, the inductibility of their proliferation and of their beta-oxidation enzymes, palmitoyl-CoA oxidase and bifunctional enzyme, were studied in control and treated cells. In Fao cells, peroxisomes are less numerous and smaller than in rat liver, but they increase in size and number under the effect of ciprofibrate, similarly to those of treated rat liver. The high peroxisome proliferation is accompanied by a strong induction of beta-oxidation enzymes as in vivo. In MH1C1 cells, peroxisomes are seen in irregular clusters in the cytoplasm, small with rounded to tubular forms, suggesting rapid peroxisomal growth. A striking observation is the particularly elongated, worm-like form of many of the peroxisomes. Under the effect of ciprofibrate, the proliferation is low, as is the induction of beta-oxidation enzymes. HepG2 cells contain few, small peroxisomes with a heterogeneity of forms, from spherical to elongated. The only peroxisomal response to ciprofibrate in these cells seemed to be a morphological reorganization. There is little or no induction of beta-oxidation enzymes by ciprofibrate in HepG2 cells, as in cultured human hepatocytes. Therefore, on the one hand, Fao and MH1C1 cells are complementary tools in the investigation of the regulation of the hepatic response to peroxisome proliferators in the rat, on the other hand, HepG2 and Fao cells are useful in the study of the species specificity of the response.
Duclos
S
S
Laboratoire de Biologie Moléculaire et Cellulaire, Faculté des Sciences Mirande, Université de Bourgogne, Dijon/France.
Bride
J
J
Ramirez
L C
LC
Bournot
P
P
D015094:3-Hydroxyacyl CoA Dehydrogenases / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured / Q000187:drug effects; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D004746:Enoyl-CoA Hydratase / Q000378:metabolism*; D011345:Fenofibrate / Q000494:pharmacology; D058607:Fibric Acids; D018197:Hepatoblastoma / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D007535:Isomerases; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D008113:Liver Neoplasms / Q000378:metabolism* / Q000648:ultrastructure; D008114:Liver Neoplasms, Experimental / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D008830:Microbodies / Q000187:drug effects* / Q000648:ultrastructure; D008854:Microscopy, Electron; D009097:Multienzyme Complexes / Q000378:metabolism*; D010088:Oxidoreductases / Q000378:metabolism*; D063994:Peroxisomal Bifunctional Enzyme; D051381:Rats; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured / Q000187:drug effects
D058607:Fibric Acids; D009097:Multienzyme Complexes; D002995:Clofibric Acid; D010088:Oxidoreductases; D015094:3-Hydroxyacyl CoA Dehydrogenases; C028427:palmitoyl CoA oxidase; C576253:EHHADH protein, human; D004746:Enoyl-CoA Hydratase; D063994:Peroxisomal Bifunctional Enzyme; D007535:Isomerases; C019304:ciprofibrate; D011345:Fenofibrate